ADC Therapuetics options one Chiome antibody, declines another

Chiome Bioscience Inc. (Tokyo:4583) said it received notification from ADC Therapeutics S.A. (Epalinges, Switzerland) that ADC intends to exercise its option to negotiate rights to LIV-1205. The exclusive, worldwide rights would cover the development and commercialization of the antibody in combination with ADC Therapeutic's payload technology to create an antibody-drug conjugate to treat cancer. Chiome would retain rights to LIV-1205 outside of the creation of ADCs. LIV-1205, a humanized mAb targeting cell surface antigen Delta like canonical Notch ligand 1 (DLL1), is in preclinical development.

Additionally, Chiome said that ADC Therapeutics will decline to exercise its option to develop ADCs containing LIV-2008b. Chiome said it will continue to develop and seek out-licensing opportunities for the human mAb against tumor-associated calcium signal transducer 2 (TROP-2), which is in preclinical development. ...